Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1316753

registered interest
date	20/05/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to implement a long-term study of immune responses in individuals vaccinated against covid-19.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	4615
answer	answer is ministerial correction date of answer 25/05/2021 answer text <p>The Department is funding several studies of immune responses to COVID-19 including the SARS-CoV-2 Immunity and Reinfection EvaluatioN (SIREN) study in health care workers; the Vivaldi study in care home residents and workers; and the COVID-19 Infection Survey led by the Office for National Statistics of repeat household visits looking at those who have antibodies to COVID-19, either from vaccination or previous infection.</p><p>The National Institute for Health Research’s Health Protection Research Unit in Respiratory Infections is also looking at the size and longevity of the immune response and Public Health England is monitoring antibody levels in individuals who have received either the Pfizer or Oxford/AstraZeneca vaccine.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 25/05/2021 16:27:38 answering member 4362 label Biography information for Edward Argar
tabling member	4385 label Biography information for Dr Philippa Whitford

1316754

registered interest
date	20/05/2021
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Coronavirus: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Chancellor of the Duchy of Lancaster and Minister for the Cabinet Office, what assessment he has made of the immunological limits of covid-19 status certification.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	4616
answer	answer is ministerial correction date of answer 25/05/2021 answer text <p>The Government committed to explore whether and how COVID-status certification might be used to reopen our economy, reduce restrictions on social contact and improve safety. As set out in the ‘COVID-19 Response - Spring 2021,’ the Government will set out its conclusions on the COVID-status Certification Review in advance of Step 4 of the Roadmap, in order to inform the safe reopening of society and the economy.</p><p>An update on the Roadmap Reviews was published on 5 April and can be found here:</p><p><a href="https://www.gov.uk/government/publications/covid-19-response-spring-2021-reviews-terms-of-reference/roadmap-reviews-update" target="_blank">https://www.gov.uk/government/publications/covid-19-response-spring-2021-reviews-terms-of-reference/roadmap-reviews-update</a>.</p> answering member constituency Portsmouth North answering member printed Penny Mordaunt grouped question UIN 4665 question first answered 25/05/2021 15:54:18 answering member 4017 label Biography information for Penny Mordaunt
tabling member	4385 label Biography information for Dr Philippa Whitford

1316755

registered interest
date	20/05/2021
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what assessment he has made of the effect of global equitable access to covid-19 vaccines on the emergence of viral variants of covid-19.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	4617
answer	answer is ministerial correction date of answer 25/05/2021 answer text <p>All viruses change constantly through mutation, and many thousands of variants of the virus that causes COVID-19 have been detected across the world. Most have little to no impact on the virus's ability to cause infections and disease, but some can pose higher risks. Variants are more likely to arise in areas of high transmission. In addition to basic public health measures, the World Health Organisation has advised that ensuring equitable access to COVID-19 vaccines will reduce virus circulation. This will ultimately lead to fewer mutations and variants.</p><p>The UK is committed to rapid, equitable access to safe and effective vaccines. We are among the largest donors to the COVAX Advance Market Commitment (AMC), committing £548 million, which leveraged $1 billion from other donors in 2020 through match funding. This support to COVAX has been critical to it supplying COVID-19 vaccines to over 120 countries, and economies. We have also committed to share the majority of our supply of any surplus vaccine doses with COVAX.</p> answering member constituency Aldridge-Brownhills answering member printed Wendy Morton question first answered 25/05/2021 13:26:10 answering member 4358 label Biography information for Wendy Morton
tabling member	4385 label Biography information for Dr Philippa Whitford

1316756

registered interest
date	20/05/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when his Department plans to publish the Government’s Vaccine Strategy.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	4618
answer	answer is ministerial correction date of answer 25/05/2021 answer text <p>England’s national vaccine strategy is being refreshed to include new developments from the COVID-19 vaccine programme and the extended National Health Service flu programme. The vaccine strategy will be published in due course.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 25/05/2021 15:34:32 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4385 label Biography information for Dr Philippa Whitford

1316758

registered interest
date	20/05/2021
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, how many covid-19 vaccine doses the UK has shared through the COVAX facility in 2021.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	4619
answer	answer is ministerial correction date of answer 25/05/2021 answer text <p>The UK remains committed to rapid, equitable access to safe and effective vaccines, and the Prime Minister has said that we will share the majority of any doses that are surplus to UK needs with COVAX. As the multilateral mechanism set up to support international cooperation on vaccines, COVAX remains best-placed for allocating vaccines where they are most needed, and will be most effective. We have already committed £548 million to the COVAX Advance Market Commitment, which specifically supports vaccine access for at least 500 million people in up to 92 low and middle income countries in 2021. Our wider support for COVAX has enabled the mechanism to reach over 120 countries.</p> answering member constituency Aldridge-Brownhills answering member printed Wendy Morton question first answered 25/05/2021 13:22:10 answering member 4358 label Biography information for Wendy Morton
tabling member	4385 label Biography information for Dr Philippa Whitford

1314000

registered interest
date	12/05/2021
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, when the Government plans to begin sharing surplus covid-19 vaccine doses through the COVAX facility in 2021.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	768
answer	answer is ministerial correction date of answer 17/05/2021 answer text <p>As the multilateral mechanism set up to support international co-operation on vaccines, and to ensure that the most vulnerable countries have access, COVAX remains best-placed to allocate any surplus doses that the UK may have where they are most needed, and will be most effective. However, it is too early to determine how many doses of the vaccines that the UK has ordered will not be needed for the UK population. This is under constant review.</p> answering member constituency Aldridge-Brownhills answering member printed Wendy Morton question first answered 17/05/2021 14:00:34 answering member 4358 label Biography information for Wendy Morton
tabling member	4385 label Biography information for Dr Philippa Whitford

1314002

registered interest
date	12/05/2021
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what recent discussions he has had with his international counterparts on sharing surplus covid-19 vaccine doses through the COVAX facility in 2021.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	769
answer	answer is ministerial correction date of answer 17/05/2021 answer text <p>The UK is committed to rapid, equitable access to safe and effective vaccines, treatments, and tests globally. The Prime Minister, Foreign Secretary, and I continue to speak to our international counterparts, discussing the shared fight against coronavirus.</p><p>For example, at the recent G7 Foreign and Development Ministerial Meeting, we agreed a statement on Equitable Access and Collaboration that recognised COVAX as &quot;the key mechanism for global sharing of vaccines…to enable the rapid equitable deployment of vaccines.&quot; We committed to supporting access to safe, effective vaccines, with distribution guided by principles of equity and public health data.</p> answering member constituency Aldridge-Brownhills answering member printed Wendy Morton question first answered 17/05/2021 14:22:31 answering member 4358 label Biography information for Wendy Morton
tabling member	4385 label Biography information for Dr Philippa Whitford

1314003

registered interest
date	12/05/2021
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, whether covid-19 vaccine dose-sharing will count towards the Official Development Assistance budget for 2021.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	770
answer	answer is ministerial correction date of answer 17/05/2021 answer text <p>The UK is a founding member, and one of the largest donors to the COVAX Advance Market Commitment, contributing £548 million for global equitable access. This £548 million spend, and the vital work it supports, has been assessed as ODA eligible, and will be met under our commitment to spend 0.5% of UK GNI on ODA.</p> answering member constituency Aldridge-Brownhills answering member printed Wendy Morton question first answered 17/05/2021 14:53:49 answering member 4358 label Biography information for Wendy Morton
tabling member	4385 label Biography information for Dr Philippa Whitford

1314004

registered interest
date	12/05/2021
answering body	Foreign, Commonwealth and Development Office
answering dept id	208
answering dept short name	Foreign, Commonwealth and Development Office
answering dept sort name	Foreign, Commonwealth and Development Office
hansard heading	COVAX: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what plans he has to allocate additional funding to the COVAX facility in 2022.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	771
answer	answer is ministerial correction date of answer 17/05/2021 answer text <p>The UK is committed to rapid equitable access to safe and effective vaccines. We are among the largest donors to the COVAX Advance Market Commitment (AMC), committing £548 million, which leveraged $1 billion from other donors through match funding in 2020. This support to COVAX has been critical in supplying COVID-19 vaccines to over 120 countries and economies. The Prime Minister has also committed to sharing the majority of any surplus vaccines with COVAX.</p><p>The UK is committed to our G7 Presidency championing equitable access to vaccines, therapeutics, and diagnostics to help the world fight COVID-19, and build back better from this pandemic. We are engaging, including with our G7 partners, on COVAX's approach for 2022, and beyond, and continue to advocate for further financial contributions to COVAX to support equitable access to COVID-19 vaccines</p> answering member constituency Aldridge-Brownhills answering member printed Wendy Morton question first answered 17/05/2021 14:02:18 answering member 4358 label Biography information for Wendy Morton
tabling member	4385 label Biography information for Dr Philippa Whitford

1308911

registered interest
date	14/04/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer: Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 June 2020 to Question 56022, what plans his Department has to recover and restart recruitment to breast cancer clinical trials.
tabling member constituency	Central Ayrshire
tabling member printed	Dr Philippa Whitford
uin	180996
answer	answer is ministerial correction date of answer 27/04/2021 answer text <p>The Department’s National Institute for Health Research (NIHR) is supporting the National Health Service to deliver clinical research through the Clinical Research Network (CRN).</p><p>The NIHR’s CRN reports that of the 92 breast cancer clinical trials that it was supporting on 21 May 2020, 36 or 39% were paused as a result of the COVID-19 pandemic. As of 15 April 2021, 30 or 83% of these paused breast cancer trials have restarted and 30 new breast cancer trials have entered the portfolio since 21 May 2020.</p><p>To enable clinical research studies that have been paused to restart and recruit successfully, including breast cancer trials, plans are being developed to manage the delivery of non-COVID-19 studies to ensure successful recovery of the portfolio. Details of these plans will be published shortly.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 27/04/2021 08:49:00 answering member 4380 label Biography information for Jo Churchill previous answer version 97253 answering member constituency Bury St Edmunds answering member printed Jo Churchill answering member 4380 label Biography information for Jo Churchill
tabling member	4385 label Biography information for Dr Philippa Whitford